Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men Whose Partners Will Undergo Through an Egg Donation Cycle
NCT ID: NCT04758260
Last Updated: 2021-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2019-02-12
2021-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We will also evaluate the influence of the sORP rate in the embryo development during the egg donation treatments; taking in account the fecundation rate, percentage of blastocyst stage arrival embryos, number of frozen embryos, implantation rate, on-going pregnancy rate and miscarriage rate.
The sperm sample will be measured by electrochemical technology using Mioxsys system for a quantitative measurement in millivolts (mV), in those male patients who participate in an egg donation assisted reproduction treatment.
After 14 days, the pregnancy stage will be available. This information will be obtained from the patient's clinical history using the human chorionic gonadotropin hormone (shCG) in blood. It will be performed either in our Clinic or externally within the usual practice derived from the treatment carried out. These values will be compared with the results obtained from sORP.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0
NCT02839447
Oxidative Stress In Semen And Male Infertility
NCT03464656
Modern Analyses of the Semen in Evaluating Male Fertility and Treatment Options of Male Infertility
NCT02932865
Investigation of The Effectiveness of Antioxidant Therapy in Oligoasthenoteratozoospermic Infertile Men
NCT06042738
Impact of Antioxidant Treatment on DNA Fragmentation Index
NCT03466229
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antioxidant Treatment
Influence of the Antioxidant Treatment in the Oxidant-reduction Potential in Seminal Plasma in Men
Antioxidant
Oral antioxidant oral intake in the 3 months prior to inclusion in the study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antioxidant
Oral antioxidant oral intake in the 3 months prior to inclusion in the study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sperm origin: ejaculate
Exclusion Criteria
* Total astenozoospermia or Severe teratozoospermia (including balloonzoospermia)
18 Years
48 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aytu BioPharma, Inc.
INDUSTRY
IVI Bilbao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
FERNANDO QUINTANA FERRAZ
Marcos Ferrando Serrano
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marcos Ferrando
Role: PRINCIPAL_INVESTIGATOR
IVI Bilbao
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IVI Bilbao
Leioa, Vizcaya, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1708-BIO-088-MM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.